Reported Earnings • May 20
First quarter 2026 earnings released: US$1.29 loss per share (vs US$1.89 loss in 1Q 2025) First quarter 2026 results: US$1.29 loss per share (improved from US$1.89 loss in 1Q 2025). Revenue: US$364.8m (up 33% from 1Q 2025). Net loss: US$17.2m (loss narrowed 31% from 1Q 2025). Board Change • May 20
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Director Amy Wilkinson was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. 공시 • Apr 29
INNOVATE Corp., Annual General Meeting, Jun 11, 2026 INNOVATE Corp., Annual General Meeting, Jun 11, 2026. 공시 • Apr 28
INNOVATE Corp. to Report Q1, 2026 Results on May 14, 2026 INNOVATE Corp. announced that they will report Q1, 2026 results After-Market on May 14, 2026 공시 • Mar 17
INNOVATE Corp. to Report Q4, 2025 Results on Mar 26, 2026 INNOVATE Corp. announced that they will report Q4, 2025 results After-Market on Mar 26, 2026 공시 • Oct 23
INNOVATE Corp. to Report Q3, 2025 Results on Nov 12, 2025 INNOVATE Corp. announced that they will report Q3, 2025 results After-Market on Nov 12, 2025 공시 • Jul 18
INNOVATE Corp. to Report Q2, 2025 Results on Aug 05, 2025 INNOVATE Corp. announced that they will report Q2, 2025 results After-Market on Aug 05, 2025 공시 • Apr 29
INNOVATE Corp., Annual General Meeting, Jun 12, 2025 INNOVATE Corp., Annual General Meeting, Jun 12, 2025. 공시 • Apr 17
INNOVATE Corp. to Report Q1, 2025 Results on May 06, 2025 INNOVATE Corp. announced that they will report Q1, 2025 results After-Market on May 06, 2025 공시 • Feb 28
INNOVATE Corp. to Report Q4, 2024 Results on Mar 31, 2025 INNOVATE Corp. announced that they will report Q4, 2024 results After-Market on Mar 31, 2025 공시 • Jan 22
INNOVATE Corp. Announces U.S. Food and Drug Administration Approved the MediBeacon TGFR for the Assessment of Kidney Function in Patients with Normal or Impaired Renal Function INNOVATE Corp. announced that the U.S. Food and Drug Administration (FDA) has approved the MediBeacon TGFR for the assessment of kidney function in patients with normal or impaired renal function. The TGFR is comprised of the TGFR Sensor, TGFR Monitor, and Lumitrace (relmapirazin) injection, a non-radioactive, non-iodinated fluorescent GFR tracer agent, which together allow assessment of kidney function by measuring the clearance rate of the fluorescent agent as it leaves the body. The approval of the TGFR by the FDA demonstrates proprietary system can provide an effective option for assessing kidney function," said Steve Hanley, CEO of MediBeacon. According to the National Kidney Foundation, CKD causes more deaths each year than breast cancer or prostate cancer. It is the under-recognized public health crisis. The potential applications for the TGFR are numerous, and look forward to exploring them with clinicians both in the hospital and outpatient settings. The timing of FDA approval aligns well with the Fourth Quarter 2024 publication by MediBeacon's Chief Scientific Officer, Dr. Richard Dorshow, et al in Kidney International with data that supports the utility of MediBeacon's patented agent Lumitrace. The TGFR met its primary efficacy endpoint as per agreement with the FDA by demonstrating a P30 value of 94% while recruiting patients with a range of GFR values and skin tones. P30 is defined as the percentage of GFR estimation falling within + - 30% of measured GFR (mGFR) values. For more information, including the FDA Summary of Safety and Effectiveness Data, refer to. 공시 • Oct 17
INNOVATE Corp. to Report Q3, 2024 Results on Nov 06, 2024 INNOVATE Corp. announced that they will report Q3, 2024 results After-Market on Nov 06, 2024 공시 • Sep 04
INNOVATE Regains Compliance with NYSE Minimum Price Requirement INNOVATE Corp. (the ‘Company’) announced that it has received a letter from the New York Stock Exchange (‘NYSE’) dated August 27, 2024 (the ‘Compliance Notice’), notifying the Company that it is no longer considered below the NYSE’s continued listing criterion of a minimum average share price of USD 1.00 over a 30 trading-day period (the ‘NYSE Minimum Price Requirement’). ‘The Company’s team shared that we have received notification from the New York Stock Exchange regaining listing compliance,’ said Paul Voigt, the Company’s Chief Executive Officer. ‘Regaining compliance with NYSE allows us to shift management and investor focus back on to our positive growth story’. Reported Earnings • Aug 08
Second quarter 2024 earnings released: EPS: US$0.16 (vs US$0.14 loss in 2Q 2023) Second quarter 2024 results: EPS: US$0.16 (up from US$0.14 loss in 2Q 2023). Revenue: US$313.1m (down 15% from 2Q 2023). Net income: US$14.1m (up US$24.6m from 2Q 2023). Profit margin: 4.5% (up from net loss in 2Q 2023). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings. 공시 • Jul 18
INNOVATE Corp. to Report Q2, 2024 Results on Aug 07, 2024 INNOVATE Corp. announced that they will report Q2, 2024 results After-Market on Aug 07, 2024 공시 • May 01
INNOVATE Corp., Annual General Meeting, Jun 13, 2024 INNOVATE Corp., Annual General Meeting, Jun 13, 2024, at 11:00 US Eastern Standard Time. Agenda: To elect the four nominees identified in the accompanying proxy statement (the “Proxy Statement”), each to hold office until the 2025 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified; to approve, on a non-binding, advisory basis, the compensation of named executive officers; and to consider other matters. 공시 • Apr 28
INNOVATE Corp. to Report Q1, 2024 Results on May 07, 2024 INNOVATE Corp. announced that they will report Q1, 2024 results After-Market on May 07, 2024 공시 • Feb 28
INNOVATE Corp. has filed a Follow-on Equity Offering in the amount of $19 million. INNOVATE Corp. has filed a Follow-on Equity Offering in the amount of $19 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: Rights Offering 공시 • Feb 27
INNOVATE Receives Written Notice from the New York Stock Exchange Regarding Non-Compliance with the Continued Listing Standard Set in Section 802.01C of the NYSE’s Listed Company Manual On February 26, 2024, INNOVATE Corp. (the ‘Company’) received a written notice (the ‘Notice’) from the New York Stock Exchange (the ‘NYSE’) that it was not in compliance with the continued listing standard set in Section 802.01C of the NYSE’s Listed Company Manual (‘Section 802.01C’), as the average closing price of the Company’s common stock (the ‘Common Stock’) was less than $1.00 per share over a consecutive 30 trading-day period. The Notice has no immediate impact on the listing of the Company’s Common Stock on the NYSE, subject to the Company’s compliance with the NYSE’s other continued listing requirements. The Company plans to notify the NYSE that it intends to regain compliance and is considering all available options that are in the best interests of the Company and its shareholders. Pursuant to Section 802.01C, the Company has a period of six months following the receipt of the Notice to regain compliance with the minimum share price requirement. The Company may regain compliance at any time during the six-month cure period if on the last trading day of any calendar month during the six-month cure period the Common Stock has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. If the Company is unable to regain compliance with the $1.00 share price rule within this period, the NYSE will initiate procedures to suspend and delist the Common Stock. 공시 • Feb 13
INNOVATE Corp. to Report Q4, 2023 Results on Mar 04, 2024 INNOVATE Corp. announced that they will report Q4, 2023 results After-Market on Mar 04, 2024 New Risk • Dec 08
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €92.5m (US$99.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-US$127m). Earnings have declined by 53% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€92.5m market cap, or US$99.8m). 공시 • Oct 31
INNOVATE Corp. to Report Q3, 2023 Results on Nov 09, 2023 INNOVATE Corp. announced that they will report Q3, 2023 results After-Market on Nov 09, 2023 공시 • Sep 22
INNOVATE Corp. to Cease Suzi Herbst as Chief Operating Officer on or Around October 20, 2023 On September 21, 2023, INNOVATE Corp. and Ms. Suzi Herbst, the Company’s Chief Operating Officer, determined by mutual agreement that Ms. Herbst’s employment with the Company would cease on or around October 20, 2023. Ms. Herbst’s resignation is not a result of any disagreement with the Company on any matter relating to its operations, policies or practices. 
